ORLANDO, Fla.–(BUSINESS WIRE)–BostonGene Corporation (BostonGene), a Boston-based biomedical software company, presented the results of its recent cancer microenvironment study during the 61st American Society of Hematology Annual Meeting and Exposition held on December 7-10, 2019. The research study examined the role of the tumor microenvironment of Diffuse Large B-Cell Lymphoma (DLBCL).
The study, conducted as part of BostonGene’s collaboration with Weill Cornell Medicine, combined whole exome and transcriptome analyses from an integrated cohort of 3,026 DLBCL patients. The cohort includes publically available data as well as prospective patients.
The study revealed that a new classification based on the tumor microenvironment is associated with clinical outcomes independently of existing molecular subtypes.Computationally predicted results demonstrated a strong correlation with response therapy obtained in murine DLBCL models for subtypes based on stromal, immune and malignant composition.
“Improving treatment outcomes for individual DLBCL patients by integrated analysis of large-scale next-generation sequencing (NGS) data including somatic variants and gene expression changes in the tumor and the tumor microenvironment is our top priority,” said Leandro Cerchietti, M.D., Associate Professor of Medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. “These promising findings bring us one step closer to achieving that goal.”
“We are proud to collaborate with Weill Cornell Medicine to provide advanced computational analytics for the integration of big data sets generated for each patient,” said Andrew Feinberg, President and CEO of BostonGene. “We look forward to continuing our collaboration to further identify the best treatment options for cancer patients.”
About BostonGene Corporation
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient’s individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.